ABSTRACT
Background The most widely used classifications of adverse events (AE) in surgical neurology assign a grade to AE that depends on the therapy used to treat them or on new neurologic deficits. Both concepts have substantial shortcomings in grading AE severity. We present a novel multidimensional approach to this challenge and aim at validating the new grading system.
Methods The new Therapy-Disability-Neurology (TDN) grading system classifies AE into five grades, depending on the associated therapy, disability, and neurologic deficits. We conducted a two-center study on 6071 interventions covering the whole neurosurgical spectrum with data prospectively recorded between January 2013 and September 2019 at the University Hospital Zurich (USZ) and at the Fondazione IRCCS Istituto Neurologico Carlo Besta (FINCB).
Findings Using data from USZ, a positive correlation was found between the severity of AE and the length of hospital stay (LOS) as well as treatment cost. Each grade was associated with a greater deterioration of the Karnofsky Performance Status Scale (KPS) at discharge and at follow-up. Additionally, there was a correlation between the severity of AE and absolute KPS values. When using the same methods on an external validation cohort from FINCB, correlations between the grade of AE, LOS, and KPS at discharge were even more pronounced.
Interpretation Our results suggest that the TDN grade is consistent with clinical and economic repercussions of AE and thus reflects AE severity. It is objective, practical, easily interpreted, and enables comparison between different medical centers. The TDN grade will constitute an important step forward towards a more precise and standardized documentation of AE and ultimately lead to a more critical and patient-centered appraisal of process and outcome measures in surgical neurology.
Funding None.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01628406
Funding Statement
This study was not funded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
USZ registry was approved upfront by the local ethics review board (PB-2017-00093) and internationally registered at clinicaltrials.gov (NCT01628406).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data will be provided upon reasonable request.
ABBREVIATIONS
- AE
- adverse event
- CDG
- Clavien-Dindo-Grading
- CI
- confidence interval
- FINCB
- Fondazione IRCCS Istituto Neurologico Carlo Besta
- IQR
- interquartile range
- KPS
- Karnofsky Performance Status Scale
- LIC
- Landriel Ibañez Classification
- LOS
- length of hospital stay
- MAE
- mean absolute error
- MCS
- Milano complexity scale
- mRS
- modified Rankin Scale
- NIHSS
- National Institutes of Health Stroke Scale
- SAVES-V2
- Spinal Adverse Events Severity System version 2
- SD
- standard deviation
- TDN
- Therapy-Disability-Neurology
- USZ
- University Hospital Zurich
